research FINASTERIDA E CALVÍCIE ANDROGENÉTICA: em busca de uma terapêutica embasada na atenção integral à saúde do homem
Finasteride is commonly used for male pattern hair loss but has potential risks, including irreversible sexual dysfunction.
Search
for
Sort by
Research
930-960 / 1000+ results research Safety and Efficacy of the Coadministration of Sildenafil and Finasteride
Taking sildenafil and finasteride together is safe and improves urinary and sexual symptoms in BPH patients.
research Synthesis and biological evaluation of 3-tetrazolo steroidal analogs: Novel class of 5α-reductase inhibitors
3-tetrazolo steroidal analogs can strongly inhibit the enzyme linked to hair loss.
research Avicequinone C Isolated from Avicennia marina Exhibits 5α-Reductase-Type 1 Inhibitory Activity Using an Androgenic Alopecia Relevant Cell-Based Assay System
Avicequinone C, a compound found in the Avicennia marina plant, can reduce hair loss by inhibiting a hormone linked to androgenic alopecia.
research Novel C-6 substituted and unsubstituted pregnane derivatives as 5α-reductase inhibitors and their effect on hamster flank organs diameter size
Certain compounds reduced hamster flank organ size by inhibiting 5α-reductase, like finasteride, without affecting androgen receptors.
research A retrospective analysis of clinical,dermoscopic features of male patients with androgenic alopecia before and after treatment
The combination of oral finasteride and topical 5% minoxidil effectively treats androgenic alopecia, especially after 3 months.
research Finasteride nano-transferosomal gel formula for management of androgenetic alopecia: ex vivo investigational approach
The new gel formula could improve the delivery of a hair loss treatment through the skin and might be an alternative to taking it by mouth.
research Study on inhibitory effect of Urtica laetevirens Maxim. extract on 5α-reductase
Urtica laetevirens extract significantly reduces 5α-reductase activity.
research Preparation and evaluation of a multimodal minoxidil microemulsion versus minoxidil alone in the treatment of androgenic alopecia of mixed etiology: a pilot study
The multimodal microemulsion with minoxidil, diclofenac, and tea tree oil is more effective for hair growth than minoxidil alone.
research Clinical study of combined prednisone with minoxidil in treatment of the androgenetic alopecia
research Abstracts from the current global literature: Finasteride and sexual dysfunction
Finasteride, a hair loss drug, can cause sexual side effects like erectile dysfunction in 2.1%-3.8% of users, but these usually go away with time or if the drug is stopped. Despite this, its impact on sexual function is minimal for most men.
research Finasteride
Finasteride helps hair growth and prostate issues but may cause sexual side effects and increase tumor risk.
research 63253 A pilot study of efficacy and safety comparing 5% minoxidil emulsion and standard topical 5% minoxidil solution in the treatment of male androgenetic alopecia
research Cortexolone 17a-propionate: A new antiandrogen acting on hair dermal papilla cells for the treatment of androgenic alopecia
Cortexolone 17a-propionate may be an effective new treatment for hair loss.
research Novedades terapéuticas en tricología
Recent advances in hair loss treatments show significant progress.
research Determination of Finasteride and Its Pharmacokinetics in Human Plasma by HPLC
Two finasteride preparations are bioequivalent.
research DHEA : why, when, and how much ? D’après la conférence de Bruno Allolio (Wuerzburg), 50e Journées internationales d’endocrinologie clinique Henri-Pierre KLOTZ, septembre 2007
DHEA supplementation may improve quality of life, neuropsychological functions, and sexual satisfaction in individuals with adrenal insufficiency, but more research is needed to confirm its safety and effectiveness.
research THE TREATMENT OF HIRSUTISM WITH A COMBINATION OF DESOGESTREL AND ETHINYL OESTRADIOL
A combination of desogestrel and ethinyl oestradiol effectively reduces hair growth in hirsute women.
research Guidelines on the use of finasteride in androgenetic alopecia
Taking 1 mg of finasteride daily can increase hair count and improve hair appearance, but it may have side effects on sexual function and a potential risk of prostate cancer. It may not be effective for postmenopausal women unless taken in higher doses.
research Exploring the efficacy of testosterone undecanoate in male children with 5α‐reductase deficiency
Testosterone undecanoate safely and effectively increased penis size in male children with 5-alpha-reductase deficiency.
research Activity of steroid 4 and derivatives 4a–4f as inhibitors of the enzyme 5α-reductase 1
Compounds 4, 4b, and 4c effectively inhibit an enzyme linked to testosterone conversion without significant toxicity.
research Finasteride in the treatment of Japanese men with male pattern hair loss.
Finasteride, especially in a 1mg dose, effectively slows hair loss and improves hair growth in Japanese men with male pattern hair loss.
research Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration
Finasteride lowers scalp and blood DHT levels, potentially treating male-pattern baldness.
research Update on minoxidil treatment of hair loss
research Re: Risk of Erectile Dysfunction Associated with Use of 5α-Reductase Inhibitors for Benign Prostatic Hyperplasia or Alopecia: Population Based Studies Using the Clinical Practice Research Datalink
Using finasteride for hair loss or prostate issues does not significantly raise the risk of erectile dysfunction.
research Clobetasol/minoxidil
research PD-02.09
Alpha-blocker therapy may not be needed long-term when combined with finasteride for BPH.
research Nanostructured Drug Delivery Systems for Targeting 5-α-Reductase Inhibitors to the Hair Follicle
Nanostructured delivery systems could potentially improve hair loss treatment by targeting drugs to hair follicles, reducing side effects and dosage, but the best size, charge, and materials for these systems need further investigation.
research Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content*
A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.
research PNU 157706, a novel dual type I and II5α-reductase inhibitor
PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.